Kornimate/medical-research-clean huggingface dataset:
an open-label, prospective study to assess the safety and effectiveness of adalimumab in patients with moderate to severe plaque psoriasis in the russian federation

Conditions: Moderate to Severe Plaque Psoriasis

Summary: this is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.

during the treatment period, participants will receive an initial adalimumab 80 milligram (mg) subcutaneous (sc) dose, followed by adalimumab 40 mg sc every other week starting one week after initial dose. safety and effectiveness assessments will be completed at baseline, week 2, week 4, week 8, week 12, week 16 and week 24. participants may discontinue adalimumab treatment at any time during study participation. participants that end study participation early will have a premature discontinuation visit. all participants who do not initiate commercial humira® will have a follow-up phone call 70 days after the last administration of study drug to obtain information on any new or ongoing adverse events (aes). the 70-day follow-up phone call will not be required for any participant that initiates adalimumab therapy not supplied in the context of the clinical trial after the end of study participation.

Eligibility criteria:
inclusion criteria: a patient will be eligible for study participation if he/she meets the following criteria: 1. male and female patients ≥ 18 years of age. 2. clinical diagnosis of psoriasis for at least 6 months as determined by patient interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator. 3. stable plaque psoriasis for at least 2 months before screening and baseline visits as determined by patient interview of his/her medical history. 4. moderate to severe plaque psoriasis defined by ≥ 10% body surface area (bsa) involvement at the baseline visit. 5. pasi (psoriasis area and severity index) score ≥ 10 at the baseline visit. exclusion criteria: 1. diagnosis of erythrodermic psoriasis, pustular psoriasis, medication induced or medication-exacerbated psoriasis or new onset of guttate psoriasis. 2. diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of psoriasis. 3. patient who cannot discontinue topical therapies for the treatment of psoriasis such as corticosteroids, vitamin d analogs, or retinoids at least 14 days prior to the baseline (week 0) visit and during the study. participants are allowed to use: * shampoos that contain no corticosteroid; * bland (without beta or alpha hydroxy acids or containing no psoriasis treatment) emollients; * low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only. 4. patient who cannot avoid uvb (ultraviolet-b) phototherapy for at least 14 days prior to the baseline (week 0) visit and during the study. 5. patient who cannot avoid puva (psoralen + ultraviolet a) phototherapy for at least 28 days prior to the baseline (week 0) visit and during the study.

Keywords: moderate to severe plaque psoriasis
jacobson's progressive muscle relaxation technique on children with leukemia undergoing chemotherapy.

Conditions: Leukemia; Children; Fatigue Related to Cancer Treatment; Anxiety

Summary: the goal of this clinical trial is to determine the effect of jacobson's progressive muscle relaxation technique on anxiety and fatigue among children with leukemia undergoing chemotherapy. the main research hypotheses are; * children with leukemia who receive jacobson's progressive muscle relaxation technique exhibit less anxiety than those who don't receive it. * children with leukemia who receive jacobson's progressive muscle relaxation technique exhibit less fatigue than those who don't receive it. researchers will compare jacobson's progressive muscle relaxation technique with standardized nursing care on a child's anxiety and fatigue.


Eligibility criteria:
inclusion criteria: * children diagnosed with leukemia and received chemotherapy sessions. * age ranged from 7 to 15 years. exclusion criteria: * other disorders such as neurological diseases, cerebrovascular accidents, or mental illness.

Keywords: jacobson&amp;#39;s progressive muscle relaxation technique anxiety fatigue children leukemia chemotherapy nursing care
performance study of targeted sequencing technology for vap

Conditions: VAP - Ventilator Associated Pneumonia

Summary: main purpose: to evaluate the feasibility of tngs for pathogen detection and drug resistance analysis in vap patients. research site and research population: this study is planned to be conducted in hospitals, targeting vap patients. perform clinical routine testing and tngs testing on lower respiratory tract samples (balf) from vap patients, and collect patient clinical information. clinical routine testing includes culture (necessary), microscopy, serology, pcr, etc., and drug sensitivity tests are conducted on positive culture samples as needed. finally, compare the consistency of tngs detection results with clinical culture, comprehensive diagnosis, and drug sensitivity results. further validation was conducted on consistent negative or inconsistent samples through pcr and mngs.

the investigators plan to include 150 vap patients in the icu. lower respiratory tract samples (balf) from vap patients were routinely tested and tngs tested, and clinical information was collected. routine clinical tests include culture (necessary), microscopic examination, serology, pcr, etc., and drug sensitivity tests are performed on positive culture samples as required. finally, the consistency of tngs test results with clinical culture, comprehensive diagnosis and drug sensitivity results was compared. the uniformly negative or inconsistent samples were further verified by pcr and mngs.

Eligibility criteria:
inclusion criteria: * (1)vap patients (2) patients can collect the required test information exclusion criteria: * (1) clearly diagnosed as non-infectious patients (2) insufficient samples or patients unwilling to participate (3) life expectancy is less than 24 hours (4) patients' clinical information cannot be obtained
efficacy of sms to improve early retention in hiv care for plwh in lima

Conditions: HIV

Summary: randomized controlled study that will evaluate the effect of a text message-based strategy to improve retention in hiv care.

this is a randomized controlled pilot study with a parallel 2-arm design. it will evaluate the effect of a text message-based strategy to improve retention in hiv care at the study clinic, compared to the standard of care. trained counselors will deliver the text messages. after a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. the nurse will send 2 tailored text messages per week. in addition 2 to 4 days before an appointment, the nurse will send a message reminder. in addition, the nurse will have bilateral communication with participants using text messages according to their needs. the participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). three and six months after started the intervention the variables of interest will be assessed.

Eligibility criteria:
inclusion criteria: * male 18 years old or older. * linked to hiv care at the study clinic. * have a cell phone. * diagnosed at the study clinic of referred from other center to start art. * give consent to participate. exclusion criteria: * enrolled in other hiv study using text messages. * have started art. * enrolled in a clinical trial.

Keywords: prevention retention mhealth
zynrelef for pain management in total knee arthroplasty

Conditions: Post Operative Pain; Osteoarthritis, Knee

Summary: the goal of this randomized controlled trial is to compare opioid medication consumption after surgery for patients who have a total knee replacement. the main questions it aims to answer are: * how well does the study drug control pain in the days after surgery? * does the study drug reduce the amount of opioid analgesic consumed after surgery? participants in the study group will undergo a total knee replacement as planned with their surgeon. in addition, be given the study drug, zynrelef (combination of bupivacaine and meloxicam). researchers will compare the above to a control group who will have a total knee replace only according to usual standards to see if there are any differences in the amount of a type of pain medication (opioid analgesic) consumed in the days following surgery.


Eligibility criteria:
inclusion criteria: 1. adult patients undergoing primary unilateral total knee arthroplasty \[current procedural terminology code: 27447\] 2. patients with a diagnosis of primary osteoarthritis \[icd-10 codes: m17.0, m17.10, m17.11, m17.12\] 3. varus deformity less than 10 degrees 4. flexion contracture less than 10 degrees 5. age 35 - 70 years old 6. bmi \< 40 7. patients who are discharged on the same day after the unilateral total knee arthroplasty procedure exclusion criteria: 1. inflammatory arthritis 2. post-traumatic arthritis 3. valgus deformity 4. severe varus (\> 10 degrees) 5. severe flexion contracture (\> 10 degrees) 6. overnight or longer hospital stay after surgery 7. prior surgery on affected knee other than knee arthroscopy for meniscal or cartilage debridement/repair 8. creatinine \> 1.2 9. chronic kidney disease (ckd) stage 3, 4, 5 or end stage renal disease 10. uncontrolled diabetes mellitus (glycated hemoglobin \> 8.0%) 11. current liver disease 12. personal history of depression or anxiety disorder 13. personal history of deep venous thrombosis (dvt) or pulmonary embolism (pe) 14. narcotic or tramadol use within 2 weeks of the planned procedure 15. allergy to aspirin, nsaids, oxycodone, tylenol, local anesthetics 16. walking aid for anything other than the operative joint 17. contraindication for use of the study drug (as specified by the manufacturer): * known hypersensitivity to local amide anesthetics, nsaids or study drug components * history of asthma, urticaria or other allergic-type reactions to aspirin or other nsaids 18. patients taking the following medications: * amitriptyline * nortriptyline * gabapentin * pregabalin * duloxetine (snri) * des-venlafaxine (snri) * cyclobenzaprine * baclofen 19. pregnant or lactating females 20. patients unable to provide informed consent 21. subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

Keywords: knee arthroplasty postoperative pain management
the effect of dynamic taping to improve the landing strategy in athletes.

Conditions: Landing Error Scoring System (LESS)

Summary: this study will be conducted in three years: in the first year, we would recruit male and female high school soccer athletes to observe the effect of dynamic taping on landing error scoring system under fatigue status. in the second year, we would recruit junior high school, high school and college athlete to establish a native model of single-leg and double-leg less, then in advanced, confirm the ability to predict acl injuries. in the third year, we will focus on high-risk subjects evaluated by less and athlete with acl reconstruction to observe the supportive effect of dynamic taping.

acl injuries occur most frequently in sports involving pivoting sudden deceleration. in taiwan, it was estimated that at least 1,000 cases of patients require acl reconstruction annually. despite the improving of surgical technique, there is only 65% patients who received the acl reconstruction return to their pre-injury level of sport. therefore, to prevent acl injuries in athletes is critical. according to previous studies, the landing error scoring system (less) is a clinical assessment tool to do field evaluation. we could predict the possibility of acl injuries by the change of biomechanics. however, there are still many factors affecting the less, such as fatigue, single or double leg landing, age, sex and specific sport...etc., and comprehensive studies are absent. dynamic taping is a newly developing technique with better elasticity and extensibility. studies showed that dynamic taping improve the biomechanics of knee joint. hence, we can adjust the faulty movement as soon as possible to prevent the occurrence of acl injuries. this study will be conducted in three years: in the first year, we would recruit male and female high school soccer athletes to observe the effect of dynamic taping on landing error scoring system under fatigue status. in the second year, we would recruit junior high school, high school and college athlete to establish a native model of single-leg and double-leg less, then in advanced, confirm the ability to predict acl injuries. in the third year, we will focus on high-risk subjects evaluated by less and athlete with acl reconstruction to observe the supportive effect of dynamic taping.

Eligibility criteria:
inclusion criteria: * 1st year: senior high school soccer athletes * 2nd year: junior/senior high school and college athlete * 3dr year: high-risk subjects evaluated by less and athlete with acl reconstruction exclusion criteria: * those who are unable to exercise due to acute joint, muscle or nerve injury in the lower extremities * lower extremity surgery within 1 year * head trauma within 6 months * those with vestibular injury within 6 months * allergic to dynamic tape * pregnant * visual coordination impairment

Keywords: dynamic taping landing error scoring system (less) acl injuries
the forgotten role of back muscle characteristics to tailor exercise therapy for recurrent non-specific low back pain

Conditions: Low Back Pain; Back Pain Lower Back Chronic

Summary: patients with non-specific low back pain will be compared to healthy, age- and sex-matched controls to determine the most discriminating back muscle characteristics and to delineate possible phenotypes of patients with non-specific low back pain showing impaired proprioceptive postural control. additionally, the group of patients with non-specific low back pain will receive a 16-week, high-load proprioceptive training program. the effects of this training program on the different back muscle characteristics and proprioceptive postural control will be evaluated.

the back-to-back study consists of a cross-sectional study and a proof-of-concept study. the cross-sectional study aims to gain more insight into the peripheral underlying mechanisms of impaired proprioceptive postural control in patients with non-specific low back pain. macroscopic, microscopic, hemodynamic, and electrophysiological characteristics of the lumbar multifidus and erector spinae muscles will be compared between patients with non-specific low back pain and healthy, age- and sex-matched controls. the interrelatedness between these back muscle characteristics and the correlation with proprioceptive postural control will be examined. the most discriminating muscle characteristics will be determined based upon which phenotypes of patients with non-specific low back pain will be delineated. the proof-of-concept study aims to assess the effects of high-load proprioceptive training on back muscle characteristics and proprioceptive postural control in patients with non-specific low back pain.

Eligibility criteria:
inclusion criteria: patients with non-specific low back pain: * aged 18-60 years * non-specific low back pain without radicular leg pain * mechanical low back pain with episodes of \ 6 on the numerical pain rating scale * non-specific low back pain for three months or more * score of 20% or more on the modified low back pain disability questionnaire * informed consent to participate healthy controls: * aged 18-60 years * no history of low back pain needing medical treatment or resulting in a limited activity level * no low back pain in the previous six months * informed consent to participate exclusion criteria: * pregnancy * previous trauma or surgery to the spine, pelvis or lower limbs * structural spinal deformity (e.g., scoliosis) * neurological, neuromuscular, respiratory or systemic disease * central sensitization: score of 50/100 or more on the central sensitization inventory * specific vestibular or balance problems * acute lower limb or neck problems * body mass index of 30 kg/m² or more

Keywords: proprioceptive postural control muscle volume muscle activation muscle oxygenation muscle fiber type composition proprioceptive training
neurofilament assay for the diagnosis of als

Conditions: Progressive Motor Neuron Disease Without Definite Diagnosis

Summary: the aim of the study is to evaluate the interest of the determination of pnfh and nfl neurofilaments in serum for the diagnosis of als in patients with a diagnostic standoff after evaluation in an expert als center. the hypothesis is that one of these biomarkers, or their combined analysis, will make it possible to confirm or invalidate the diagnosis of als.

for this study, which aims to evaluate a test to help in the diagnosis of als that could be integrated into routine practice, it was preferred to use blood tests. blood sampling is significantly less invasive than csf sampling, and more easily generalized, including in ambulatory conditions.

Eligibility criteria:
inclusion criteria : subjects with first and/or second motor neuron disease, evolving clinically and/or electrically over at least 12 months, not meeting the diagnostic criteria for als (revised el escorial criteria): * isolated peripheral motor neuron disease (at least one region of the pnm) or * isolated central motor neuron involvement (at least two areas of the mnc) or * associated involvement of the mnp and mnc but in the presence of an associated pathology responsible for a persistent diagnostic doubt (double narrow cervical and lumbar canal, associated evolving cancer evoking a paraneoplastic syndrome without specific antibody found) age superior to 18 years management and follow-up in one of the french als centers patient able to express his non-opposition affiliation with social security or beneficiary of such a plan non-inclusion criteria: refusal of the patient person under a legal protection measure (guardianship, curatorship or safeguard of justice). person deprived of liberty by judicial or administrative decision.

Keywords: als neurofilaments nfl pnfh amyotrophic lateral sclerosis progressive motor neuron disease
a comparative study between radius and capitate shortening in ulna minus variance kienbock's disease

Conditions: Avascular Necrosis of Lunate

Summary: 1. kienböck's disease refers to avascular necrosis of the lunate carpal bone, known as lunatomalacia. it was first recognized and described by austrian radiologist robert kienböck's in 1910 2. the lunate is the central bone in the proximal row, and it articulates with the scaphoid, capitate, triquetrum, and occasionally the hamate. more proximally, the lunate is a component of the radiocarpal joint, and it also articulates with the ulna via the triangular fibrocartilage complex (tfcc) 3. the exact cause of kienböck's is not known, though there are thought to be a number of factors predisposing a person to kienböck's. although there is no evidence that kienböck's disease is inherited, it is possible that unidentified genetic factors could contribute to the development of the condition, it is multifactorial, related to the following variables:ulnar negative variance (or ulna minus),vascular supply to the lunate bone,lunatemorphology,radial inclination angle,multiple wrist trauma 4. kienböck's disease is the second most common type of avascular necrosis of the carpal bones, preceded only by avascular necrosis of the scaphoid. the typically affected population is males aged 20-40 years 5. patients usually present with unilateral pain over the dorsal aspect of the wrist, limited wrist motion, weakness, or a combination of the three. wrist extension and axial loading exacerbate pain. symptoms range from mild to debilitating. it is rarely bilateral, and trauma is often absent. physical examination commonly reveals wrist swelling, tenderness over the expected location of the lunate, synovitis, and loss of grip strength 6. kienböck's disease is a clinical and imaging diagnosis. both radiography/computed tomography and magnetic resonance imaging (mri) are highly specific. however, mri is the most sensitive and detects radiographically occult cases


Eligibility criteria:
inclusion criteria: * age : 18-65 years. * stages ii \& iii. * ulna minus. exclusion criteria: * teens. * serious medical condition. * stage i\& iv. * sever osteoporosis.
genetic determinants of the response to salbutamol among asthma patients

Conditions: Asthma

Summary: the response to salbutamol varies greatly among individuals. data from previous studies indicate that some of the variability is accounted for by genetic polymorphisms in the gene encoding for the adrenoceptor subtype β2. the current study was designed to evaluate variability in the response to salbutamol among recently diagnosed patients who have not been treated by β2 agonists or corticosteroids. lung function tests will be performed prior to and following a single dose administration of salbutamol through inhalation. additional pharmacodynamic indices will be monitored including pulse and blood pressure. three samples of plasma will be drawn for the evaluation of salbutamol plasma concentration.


Eligibility criteria:
inclusion criteria: * 18 years and older * recently diagnosed as asthmatic exclusion criteria: * current treatment by β2 agonist * current treatment by corticosteroids * acute asthma attack

Keywords: albuterol β2 adrenergic receptor polymorphism